Tags

Type your tag names separated by a space and hit enter

Tissue factor and cancer.
Pathophysiol Haemost Thromb. 2008; 36(3-4):160-76.PH

Abstract

Tissue factor (TF), the key regulator of haemostasis and angiogenesis, is also involved in the pathology of several diseases, including cardiovascular, inflammatory and neoplastic conditions. In the latter, TF is upregulated by cancer cells, as well as by certain host cells, and it is the interactions between these distinct pools of TF-expressing cells that likely influence tumour progression in several ways. Furthermore, the release of TF microparticles into the circulation is thought to contribute to the systemic coagulopathies commonly observed in cancer patients. The direct regulation of TF by oncogenic events has provided a plausible explanation for the relatively common overexpression of TF in various cancers and its involvement in tumour growth, angiogenesis, metastasis and coagulopathy. However, this constitutive influence is modified by the tumour microenvironment, cellular interactions and host factors rendering TF expression patterns complex and heterogeneous. It appears that in many biological contexts TF plays a central role in disease progression and thereby potentially constitutes an attractive therapeutic target, especially in scenarios where the risk of bleeding can be avoided by selecting appropriate medications, refined dosing or by targeting the signalling component of TF activity. The efficacy and safety of such approaches still awaits clinical verification.

Authors+Show Affiliations

Henderson Research Centre, McMaster University, Hamilton, Ont., Canada.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19176989

Citation

Milsom, Chloe, and Janusz Rak. "Tissue Factor and Cancer." Pathophysiology of Haemostasis and Thrombosis, vol. 36, no. 3-4, 2008, pp. 160-76.
Milsom C, Rak J. Tissue factor and cancer. Pathophysiol Haemost Thromb. 2008;36(3-4):160-76.
Milsom, C., & Rak, J. (2008). Tissue factor and cancer. Pathophysiology of Haemostasis and Thrombosis, 36(3-4), 160-76. https://doi.org/10.1159/000175154
Milsom C, Rak J. Tissue Factor and Cancer. Pathophysiol Haemost Thromb. 2008;36(3-4):160-76. PubMed PMID: 19176989.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tissue factor and cancer. AU - Milsom,Chloe, AU - Rak,Janusz, Y1 - 2009/01/27/ PY - 2009/1/30/entrez PY - 2009/1/30/pubmed PY - 2009/3/3/medline SP - 160 EP - 76 JF - Pathophysiology of haemostasis and thrombosis JO - Pathophysiol Haemost Thromb VL - 36 IS - 3-4 N2 - Tissue factor (TF), the key regulator of haemostasis and angiogenesis, is also involved in the pathology of several diseases, including cardiovascular, inflammatory and neoplastic conditions. In the latter, TF is upregulated by cancer cells, as well as by certain host cells, and it is the interactions between these distinct pools of TF-expressing cells that likely influence tumour progression in several ways. Furthermore, the release of TF microparticles into the circulation is thought to contribute to the systemic coagulopathies commonly observed in cancer patients. The direct regulation of TF by oncogenic events has provided a plausible explanation for the relatively common overexpression of TF in various cancers and its involvement in tumour growth, angiogenesis, metastasis and coagulopathy. However, this constitutive influence is modified by the tumour microenvironment, cellular interactions and host factors rendering TF expression patterns complex and heterogeneous. It appears that in many biological contexts TF plays a central role in disease progression and thereby potentially constitutes an attractive therapeutic target, especially in scenarios where the risk of bleeding can be avoided by selecting appropriate medications, refined dosing or by targeting the signalling component of TF activity. The efficacy and safety of such approaches still awaits clinical verification. SN - 1424-8840 UR - https://www.unboundmedicine.com/medline/citation/19176989/Tissue_factor_and_cancer_ L2 - https://www.karger.com?DOI=10.1159/000175154 DB - PRIME DP - Unbound Medicine ER -